Coherus Biosciences announces data from Phase 1b trial of CHS-114

Coherus Oncology announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic HNSCC. These data are being presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer, SITC, being held November 5-9, 2025, in National Harbor, Maryland. This interim analysis from the dose expansion phase demonstrates that CHS-114-mediated immune activation is significantly enhanced and sustained with toripalimab in HNSCC study participants. In on-treatment tumor biopsies, CHS-114 depleted CCR8+ Tregs, but not CCR8- Tregs, and increased CD8+ T cells in the tumor microenvironment, indicating TME remodeling for antitumor immune activation and establishing proof of mechanism. Key findings: CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma patients; CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a greater than50% increase in intratumoral CD8 T cells